Is Theravance Biopharma, Inc. (TBPH) Overvalued?
We dive into why Theravance Biopharma, Inc. (TBPH) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Commentary & Analysis
What You Need to Know About Theravance Biopharma, Inc.'s Q3 Earnings
Theravance Biopharma, Inc.'s fiscal Q3 earnings report was released on Monday, August 10. Let's dive in to see if (TBPH) missed or beat analyst's expectations.Jenna Brashear
What You Need to Know About Theravance Biopharma, Inc.'s Q2 Earnings
Theravance Biopharma, Inc.'s fiscal Q2 earnings report was released on Thursday, May 07. Let's dive in to see if (TBPH) missed or beat analyst's expectations.Jenna Brashear
What You Need to Know About Theravance Biopharma, Inc.'s Q1 Earnings
Theravance Biopharma, Inc.'s fiscal Q1 earnings report was released on Thursday, March 19. Let's dive in to see if (TBPH) missed or beat analyst's expectations.Tudor Pop
Why Theravance Biopharma, Inc.’s (TBPH) Stock Is Down 30.29%
As of Tuesday, March 03, Theravance Biopharma, Inc.’s TBPH share price has dipped by 30.29%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | TBPH | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $880.0 | $618.0 | 43% |
|
| Shares Out (Mil) | 51.7 | 44.8 | 48% |
|
| Institutional Ownership | 88.3% | 85.3% | 56% |
|
| Float (Mil) | 25.8 | 47.4 | 33% |
|
| Beta | 0.25 | 0.70 | 15% |
|
| Avg Daily Volume (000s) | 639 | 390 | 62% |
|
| Price Change (52-week) |
26.0% | 68.6% | 66% |
|
| Growth | TBPH | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 8.4% | 6.7% | 52% |
|
| Net Income (5yr) | 18.9% | (1.6%) | 71% |
|
| EPS (5yr) | 19.7% | 14.9% | 68 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 46.7% | (14.9%) | 93% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 2 | |
| Current EPS | $0.200 | $0.210 | $1.275 | |
| Month Ago EPS | $0.200 | $0.210 | $0.800 | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | $0.200 | $0.210 | $1.255 | |
| Year/Year Chg | (275.4%) | (89.8%) | (36.2%) | |
| Financials | TBPH | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $104 | $291 | 27% |
|
| Net Income (TTM) (Mil) | $54 | ($11) | 55% |
|
| EPS (TTM) | $1.053 | ($0.700) | 61% |
|
| Operating Cash Flow (TTM) (Mil) | $54 | ($6) | 47% |
|
| Net Cash Flow (TTM) (Mil) | ($62) | $5 | 18% |
|
| Long-Term Debt (Q1) (Mil) | $28 | $6 | 34% |
|
| Enterprise Value (Q1) (Mil) | $529 | $450 | 35% |
|
| Valuation | TBPH | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.04 | 2.78 | 65% |
|
| P/E | 16.2 | 17.4 | 40% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.8 | 1.1 | 39% |
|
| Ratios | TBPH | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 75.1% | 67.0% | 85% |
|
| Net Margin | 51.6% | (2.3%) | 97% |
|
| ROA | 12.0% | (22.4%) | 90% |
|
| ROE | 20.9% | (20.2%) | 80% |
|
| Liabilities to Assets | 38.3% | 32.2% | 29% |
|
| F-Score | 7 | 3 | 82% |
|
Theravance Biopharma, Inc. did not pass any screens on 8/20/2026.
